Pliant Therapeutics, Inc.
PLRX
$1.49
$0.042.76%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 0.00 | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 0.00 | 0.00 |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | 0.00 | 0.00 |
| SG&A Expenses | 57.68M | 59.31M | 59.06M | 58.38M | 59.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 219.86M | 234.91M | 228.37M | 222.08M | 207.75M |
| Operating Income | -219.86M | -234.91M | -228.37M | -222.08M | -207.75M |
| Income Before Tax | -206.96M | -219.52M | -210.30M | -201.68M | -185.41M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -206.96 | -219.52 | -210.30 | -201.68 | -185.41 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -206.96M | -219.52M | -210.30M | -201.68M | -185.41M |
| EBIT | -219.86M | -234.91M | -228.37M | -222.08M | -207.75M |
| EBITDA | -217.98M | -232.85M | -226.24M | -219.95M | -205.71M |
| EPS Basic | -3.39 | -3.61 | -3.47 | -3.34 | -3.09 |
| Normalized Basic EPS | -2.12 | -2.26 | -2.17 | -2.09 | -1.93 |
| EPS Diluted | -3.39 | -3.61 | -3.47 | -3.34 | -3.09 |
| Normalized Diluted EPS | -2.12 | -2.26 | -2.17 | -2.09 | -1.93 |
| Average Basic Shares Outstanding | 244.19M | 243.19M | 242.15M | 241.20M | 240.16M |
| Average Diluted Shares Outstanding | 244.19M | 243.19M | 242.15M | 241.20M | 240.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |